Novo Nordisk to Sell Obesity Drug in Big EU Markets in 2023 (1)

Novo Nordisk A/S will sell its Wegovy obesity drug in larger European markets in 2023 after resolving production problems that has held back sales of the weekly injection in the US.

Based on what the company has already seen in launches in Denmark, Norway and the US, “we’ll gradually be rolling out to more markets including also larger European markets” this year, Chief Executive Officer Lars Fruergaard Jorgensen said in an interview Tuesday. He declined to comment on exactly which markets will be added this year, although he’s earlier said that the UK will be among them.

Watch: Novo Nordisk CEO Lars Fruergaard Jorgensen talks about demand for the obesity drug Wegovy.

Source: Bloomberg

Demand ...